PREDNOS 2

PREDNOS 2 is a national multicentre double blind randomised controlled trial of short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome (SSNS).

The PREDNOS 2 trial is now complete. Trial reports will be published in the near future.

Important Message: COVID-19
We are now home-based during the COVID-19 pandemic but available and working. Responses may however take longer than normal as staff may be working altered hours but we are cross covering trials as required and urgent matters will be dealt with promptly. Please do not contact our usual office/landline number and instead email the trial contact and copy in the trial mailbox. If a query requires a prompt response please mark as ‘urgent’ in the email subject header.

Trial details

Full Title: Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome

Short Title: PREDNOS 2 study

Aim of the study: To evaluate the effectiveness of a six day course of daily prednisoline therapy at the time of Upper Respiratory Tract Infection (URTI) in reducing the development of subsequent nephrotic syndrome relapse in children with relapsing SSNS.

Study design: Double blind randomised controlled trial (RCT).

Sample size: 360 patients will be recruited into the study (180 in each arm). 365 patients were randomised, with the final patient recruited on 31st of January 2019.

Study Duration: The accrual period is for 71 months and all patients will be followed up for 12 months. The end of trial will be 6 months after the last data capture. The last data capture will be 12 months following recruitment of the last patient. The total study duration is 94 months.

Timeframes: NIHR HTA grant start date: 1st October 2012. Trial set up took place in 5 months, recruitment will take 71 months, all patients will be followed up for 12 months and 6 months has been allocated for data analysis and report writing. The first patient was randomised on 19th March 2013.

PREDNOS 2 Protocol V3.0 (1st August 2018)

__________________________________________

Chief Investigator: Dr Martin Christian

Trial Co-Sponsor: Manchester University NHS Foundation Trust and University of Birmingham (Ref: RG_12-188)

Funding: National Institute for Health Research Health Technology Assessment programme (NIHR HTA) Ref: 11/129/261

EudraCT Number: 2012-003476-39

MHRA CTA: 21761/0281/001-0001 (28th November 2012)

Research Ethics Committee: North West GM Central (Ref: 12/NW/0766) (4th December 2012)

ISRCTN10900733

NIHR CRN Study ID: 13410